Cancer Research Technology Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cancer Research Technology Ltd. - overview
Established
2002
Location
London, England, UK
Primary Industry
Biotechnology
About
Founded in 2002 and based in London, UK, Cancer Research Technology Ltd. operates as a developer and manufacturer of cancer treatment, vaccines, diagnostics and technologies.
Primary Industry
Biotechnology
Sub Industries
Pharmaceuticals
Website
www.cancertechonology.co.uk
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Cancer Research Technology Ltd. - timeline of key events
Cancer Research Technology Ltd. - financials
| Fiscal Year Ended | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 32,721,505 | 36,702,000 | 49,654,000 | 61,992,000 | 61,861,000 | 79,244,000 | 82,349,000 | 93,898,000 | 114,622,000 | 106,417,000 | 91,355,000 | 92,194,000 | - | - | - |
| % Revenue Growth (YoY) | - | 12.2% | 35.3% | 24.8% | (0.2%) | 28.1% | 3.9% | 14.0% | 22.1% | (7.2%) | (14.2%) | 0.9% | - | - | - |
| EBITDA (USD) | 2,792,108 | 4,757,000 | 8,769,000 | 20,890,000 | 20,755,000 | 21,456,000 | 36,013,000 | 35,826,000 | 47,114,000 | 38,780,000 | 32,846,000 | 32,817,000 | - | - | - |
| Operating Income (USD) | 2,131,667 | 4,133,000 | 8,322,000 | 20,435,000 | 20,388,000 | 21,059,000 | 35,546,000 | 35,262,000 | 46,419,000 | 37,953,000 | 32,075,000 | 31,970,000 | - | - | - |
| Operating Margin | 6.5% | 11.3% | 16.8% | 33.0% | 33.0% | 26.6% | 43.2% | 37.6% | 40.5% | 35.7% | 35.1% | 34.7% | - | - | - |
| % EBITDA Margin | 8.5% | 13.0% | 17.7% | 33.7% | 33.6% | 27.1% | 43.7% | 38.2% | 41.1% | 36.4% | 36.0% | 35.6% | - | - | - |
| NET Income (USD) | 1,039,908 | 1,997,000 | 976,000 | (2,068,000) | (167,000) | (3,499,000) | 7,880,000 | 56,000 | 5,277,000 | (4,288,000) | 3,588,000 | 870,000 | - | - | - |
| % Net Margin | 3.2% | 5.4% | 2.0% | (3.3%) | (0.3%) | (4.4%) | 9.6% | 0.1% | 4.6% | (4.0%) | 3.9% | 0.9% | - | - | - |
Cancer Research Technology Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seed | Completed | GammaDelta Therapeutics Ltd. | - | ||||||||
| Series A | Completed | Mission Therapeutics Ltd. | - |
Displaying 1 - 2 of 2
Cancer Research Technology Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.